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In vivo impact of presynaptic calcium channel
dysfunction on motor axons in episodic
ataxia type 2
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Ion channel dysfunction causes a range of neurological disorders by altering transmembrane ion ﬂuxes, neuronal or muscle
excitability, and neurotransmitter release. Genetic neuronal channelopathies affecting peripheral axons provide a unique oppor-
tunity to examine the impact of dysfunction of a single channel subtype in detail in vivo. Episodic ataxia type 2 is caused by
mutations in CACNA1A, which encodes the pore-forming subunit of the neuronal voltage-gated calcium channel Cav2.1. In
peripheral motor axons, this channel is highly expressed at the presynaptic neuromuscular junction where it contributes to
action potential-evoked neurotransmitter release, but it is not expressed mid-axon or thought to contribute to action potential
generation. Eight patients from ﬁve families with genetically conﬁrmed episodic ataxia type 2 underwent neurophysiological
assessment to determine whether axonal excitability was normal and, if not, whether changes could be explained by Cav2.1
dysfunction. New mutations in the CACNA1A gene were identiﬁed in two families. Nerve conduction studies were normal, but
increased jitter in single-ﬁbre EMG studies indicated unstable neuromuscular transmission in two patients. Excitability properties of
median motor axons were compared with those in 30 age-matched healthy control subjects. All patients had similar excitability
abnormalities, including a high electrical threshold and increased responses to hyperpolarizing (P50.00007) and depolarizing
currents (P50.001) in threshold electrotonus. In the recovery cycle, refractoriness (P5 0.0002) and superexcitability (P50.006)
were increased. Cav2.1 dysfunction in episodic ataxia type 2 thus has unexpected effects on axon excitability, which may reﬂect an
indirect effect of abnormal calcium current ﬂuxes during development.
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Introduction
Episodic ataxia type 2 (EA2) is an autosomal dominant
disorder caused by mutations in the CACNA1A gene,
which encodes the 1A subunit of the presynaptic
P/Q-type calcium channel Cav2.1 (Gancher and Nutt,
1986; Ophoff et al., 1996). The channel is widely ex-
pressed in the CNS, particularly in the cerebellum and
hippocampus (Vacher et al., 2008), and in spinal motor
neurons (Westenbroek et al., 1988). Large myelinated
motor axons in peripheral nerve express Cav2.1 calcium
channels at the presynaptic membrane at the neuromuscu-
lar junction, where, together with N-type Cav2.2 channels,
they trigger action potential-evoked neurotransmitter re-
lease (Day et al., 1997), but in rodents, Cav2.1 channels
are not normally expressed in peripheral axons between
the cell body and the neuromuscular junction (Ousley and
Froehner, 1994; Vogel and Schwarz, 1995; Plant et al.,
1998). This also seems to be true for human axons
(Schwarz et al., 1995; Protti et al., 1996). However,
Cav2.1 channels have been reported during development
in neonatal rodent optic nerve axons (‘developing central
axons’), where they contribute to normal action potential
propagation (Alix et al., 2008). As indicated by Alix et al.
(2008), the 1A subunits that form P/Q channels are tran-
siently clustered in the axolemma of immature axons and
are expressed where the underlying vesiculotubular com-
plex is fusing with the axolemma, including regions where
development of node of Ranvier is occurring. Mutations
of either the 1A subunit or the 22 subunit resulted in
malformed nodes of Ranvier in mice, manifesting morpho-
logically as loss of nodal protein localization, disruption
of the nodal membrane and build-up of vesicles under the
nodal axolemma (Alix et al., 2008). It was hypothesized
that disrupting calcium channel localization has either a
‘direct’ effect on node of Ranvier development due to a
disruption in vesicle docking at the nodal axolemma, or
an ‘indirect’ effect, stemming from a reduction in axonal
excitability (Alix et al., 2008).
Patients with EA2 manifest an intermittent cerebellar dis-
turbance, which can last hours to days (Jen et al., 2007).
Some patients develop ﬁxed or progressive cerebellar fea-
tures, and there is an increased incidence of epilepsy in
patients with EA2 (Rajakulendran et al., 2010). The con-
dition is allelic with spinocerebellar ataxia type 6 (SCA6),
and familial hemiplegic migraine type 1 (FHM1), and there
may be clinical overlap between these disorders (Battistini
et al., 1999; Jen et al., 1999; Kors et al., 2004). Intermittent
myasthaenia-like weakness has been reported in some pa-
tients with EA2 (Jen et al., 1999). During nerve conduction
studies in these patients, repetitive stimulation and volun-
tary contractions can produce features suggestive of vari-
able presynaptic endplate function (Jen et al., 2001; Melzer
et al., 2010), and there may be neurophysiological evidence
of a disturbance of transmission across the neuromuscular
junction (Maselli et al., 2003).
We have previously reported highly stereotypic changes
in the excitability of motor axons in the median nerve of
patients with episodic ataxia type 1 (EA1), which is caused
by loss-of-function mutations of the potassium channel
gene KCNA1 (Tomlinson et al., 2010). These changes in
excitability are not unexpected, because the Kv1.1 subunit
encoded by KCNA1 is expressed in the juxtaparanodal
membrane of motor axons, and EA1 patients commonly
exhibit neuromyotonia. We have also observed abnormal
axonal excitability in subjects with mutations in KCNQ2
channel gene responsible for slower K+ currents. These
subjects had a history of benign familial neonatal epilepsy,
but were asymptomatic when studied and did not have
neuromyotonia (Tomlinson et al., 2012).
The purpose of the present study was to evaluate whether
EA2 patients would have changes in axonal excitability,
even though calcium channels are not normally expressed
in mid-axon (at the site of stimulation), and axonal func-
tion is normal in routine nerve conduction studies.
Materials and methods
Eight patients with a clinical phenotype of EA2 were studied in
the UK, USA and Australia between 2007 and 2009 by the
same clinician (S.T.), who performed the nerve excitability stu-
dies on patients and control subjects contemporaneously. All
subjects were over the age of 18 and provided written informed
consent. Ethical approval was obtained from the Joint National
Hospital for Neurology and Neurosurgery/University College
London Ethics Committee, The University of Rochester Ethics
Committee, and the University of Sydney Human Research
Ethics Committee. They were assessed clinically and, where pos-
sible, using nerve conduction studies (including repetitive stimu-
lation), EMG, single ﬁbre EMG, and stimulated single ﬁbre
EMG, according to a previously described protocol (Mills,
2005; Tomlinson et al., 2009). Medications were not changed
for assessment. Two subjects (Subjects 3 and 5) were not taking
acetazolamide at the time of clinical or neurophysiological as-
sessment. Genomic DNA was extracted from peripheral blood
leucocytes using standard procedures. Probands were screened
for CACNA1A mutations [NCBI transcript NM_001127221.1
(on LRG_7)] by standard bidirectional Sanger sequencing of all
coding exons and exon–intron boundaries (primer sequences
available on request). Dosage analysis for CACNA1A exonic
deletions and duplications was performed by multiplex liga-
tion-dependent probe ampliﬁcation (MRC).
Nerve excitability studies
In previous publications, the terms ‘nerve excitability studies’
and ‘axonal excitability studies’ have been used interchange-
ably, and the latter will be used in this article. Excitability
studies were performed on motor axons in the median nerve
using the TROND E protocol (Kiernan et al., 2000; Burke
et al., 2001), and were analysed with Qtrac software (UCL
Institute of Neurology, UK). The studies were performed at
attack-free times, not during an ictus. During a 15-min
study, the median nerve was stimulated at the wrist with the
anode placed 10 cm more proximally over muscle, lateral to
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the median nerve. The compound muscle action potential
(CMAP) was recorded over the abductor pollicis brevis. The
reference electrode was placed distally, over the distal inter-
phalangeal joint of the thumb. The Qtrac program generated
stimulus waveforms via a data acquisition board (National
Instruments; NI USB 6221), which were delivered to the sub-
ject by a DS5 isolated linear bipolar current stimulator
(Digitimer). There were four parts to the test. Nerve excitabil-
ity studies ﬁrst evaluated the stimulus–response relationship.
From the stimulus–response curve, a ‘target’ response was set
to the steepest part of the curve, where the thresholds of the
motor axons are most concentrated, 40% of the maximal
CMAP amplitude.
Subsequent measurements in the protocol were based on
‘threshold tracking’, in which the current required to produce
the target CMAP is referred to as a ‘threshold’ for that CMAP.
Conditioning stimuli were applied to the nerve, and the change
in stimulus required to produce the target CMAP response was
‘tracked’. There were three manipulations designed to measure:
(i) strength-duration properties; (ii) the responses to subthres-
hold conditioning stimuli; and (iii) the responses to supramax-
imal conditioning stimuli. Each provides information about
different inﬂuences on membrane potential and ion channel
function.
Strength–duration properties
Strength–duration measurements of nerve membrane reﬂect
properties of the nodes of Ranvier, and can provide insight
into persistent Na+ conductances active at the resting potential
(Bostock and Rothwell, 1997). The measurement was made
using unconditioned test stimuli of different duration (0.2,
0.4, 0.6, 0.8 and 1.0ms). As stimulus duration increased, a
smaller current was required to produce the target CMAP.
Using these measurements, rheobase and the strength–duration
time constant (sd) were calculated from a plot of stimulus
charge against stimulus duration.
Threshold electrotonus
During threshold electrotonus (TE), subthreshold polarizing
currents were applied for 100ms, and the change in threshold
was tested at different times, before and during the 100ms
polarizing currents and for 100ms afterwards. The condition-
ing stimuli were hyperpolarizing (TEh) or depolarizing (TEd),
and were set at strengths of 20% (TEd20 or TEh20) and 40%
(TEd40 or TEh40) of the unconditioned threshold current
(which was monitored throughout the recording). Threshold
electrotonus can provide insight into the state of membrane
polarization and the activity of some voltage-dependent ion
channels: nodal Na+ channels and slow K+ channels, and
internodal K+ and hyperpolarization-activated, cyclic nucleo-
tide-gated (HCN) channels (Bostock et al., 1998; Howells
et al., 2012).
Current/threshold relationship
The current/threshold (I/V) relationship measured the change
in threshold at the end of a 200ms conditioning current,
which was varied in 10% steps from 50% (depolarizing) to
100% (hyperpolarizing). The resting I/V slope is the slope of
the current–threshold relationship at resting membrane poten-
tial. The minimum I/V slope is the minimum slope of the cur-
rent–threshold curve. The hyperpolarizing I/V slope: slope of
the current–threshold relationship for hyperpolarizing currents
of 80% to 100% of threshold. These data allowed rectify-
ing currents to be assessed; K+ currents with depolarization
and inwardly rectifying HCN currents (Ih) with hyperpolariza-
tion. The slope of the I/V curve is analogous to conductance.
Recovery cycle
The recovery cycle consists of the relative refractory period
(RRP, largely reﬂecting recovery of nodal Na+ channels
from inactivation), the superexcitable period (due to the depo-
larizing after potential, which can be affected by the activity of
fast K+ channels), and the late subexcitable period (reﬂecting
the slowly decaying hyperpolarization following slow K+
channel activation) (Bostock et al., 1998; Burke et al., 2009;
Howells et al., 2012). In the TROND protocol, the recovery
cycle was measured using a supramaximal conditioning stimu-
lus. The change in threshold was tracked at intervals up to
200ms after the conditioning stimulus. The conditioning po-
tential was subtracted on-line from the response to the condi-
tioning and test stimulus pair so that accurate measurements
could be made at short conditioning-test intervals.
Statistical analysis
Control data for nerve excitability studies were obtained from
age-matched subjects from a database of healthy volunteers
(Table 2). Statistical analysis was performed by the
QTRACP software (version 23/10/2012). Differences in mean
nerve excitability measures between patients and controls were
assessed by Welch’s unequal variance t-test. Because we were
interested in which measurements were different, rather than in
whether any measurements were different, Bonferroni correc-
tion was not applied, and P5 0.05 was considered signiﬁcant.
Mathematical modelling
A mathematical model of axonal excitability was applied to
the data generated from the studies (Bostock et al., 1995;
Kiernan et al., 2005a; Jankelowitz et al., 2007; Howells
et al., 2012). The means and standard deviations (SDs) of
each recorded data point were evaluated for the 30 normal
subjects and the eight patients. The conductances of the
model were ﬁrst adjusted to minimize the discrepancy between
the model and the mean control recordings, where discrepancy
was deﬁned as the weighted sum of the error terms: ([xm xn]
/ sn)
2, where xm is the threshold of the model, xn is the mean,
and sn is the standard deviation of the thresholds for the real
nerves. The weights were the same for all thresholds of the
same type (e.g. recovery cycle) and were chosen to give total
weights to the four different types of threshold measurement:
threshold electrotonus, current–threshold relation, recovery
cycle, and strength–duration time constant in the ratio
4:2:2:1. As in previous modelling studies, these ratios reﬂect,
albeit crudely, that the four threshold electrotonus traces pro-
vide more information about membrane properties than the
current/threshold relationship or the recovery cycle, which in
turn provide more information than the strength–duration re-
lationship. The ‘control’ model was achieved when the discrep-
ancy could not be further reduced by changing any of 29
parameters in the model, alone or in combination. Then, for
each of the 17 parameters in the model (comprising 10 con-
ductances, three capacitances, 15 channel gating parameters
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and the resting membrane potential), either alone or in com-
bination. To explore possible explanations for the abnormal
excitability properties of axons in EA2 a different strategy was
used: selected model parameters were tested one at a time to
see how well changes in a single parameter could account for
the abnormalities. The modelling and the ﬁtting of the model
to the control and patient recordings were carried out by
the MEMFIT function within the QTRACP program (version
23/10/2012).
Results
Subject characteristics
Eight patients with genetically conﬁrmed EA2 from ﬁve
families were studied. Clinical features are summarized in
Table 1. Subjects 1 and 2 were dizygotic twins. A family
history of EA2 was deﬁned in seven patients. All subjects
gave a history of intermittent cerebellar dysfunction lasting
hours to days, triggered by stress/emotion, intercurrent ill-
ness and vigorous exertion or sudden movement. All pa-
tients demonstrated a clinical response to acetazolamide
but this was discontinued in two because of side effects
(Subject 3 due to renal calculi; Subject 5 due to thrombo-
cytopaenia). Subjects 3 and 5 were both from Family 2 and
reported feeling muscle weakness in association with their
ataxic episodes.
Nerve conduction studies and EMG were performed in
six of eight subjects. No signiﬁcant abnormalities were de-
tected on concentric needle EMG, nerve conduction or on
repetitive stimulation of motor nerves at various rates.
However, increased jitter was demonstrated on single
ﬁbre EMG (Fig. 1A) in Subjects 3 and 5 from Family 2,
both of whom reported weakness during attacks. In add-
ition, Subject 5 (in Family 2) had increased jitter with
blocking on stimulated single ﬁbre EMG, which was max-
imal at low stimulation rates (2–5Hz; Fig. 1B). These ﬁnd-
ings demonstrate instability of neuromuscular transmission
in these subjects.
Genetic results
New mutations were found in Families A and B (Table 1).
In Family A, the mutation in exon 24: c.3992 + 1G4A p.?
affects a consensus splice donor site. The consequence of
this change is not predictable but is likely to cause a skip of
exon 24, which would introduce a premature stop after the
inclusion of three aberrant amino acids, which in turn pre-
dicts subsequent nonsense mediated decay of the aberrant
message and may prevent translation of the mRNA.
The mutation identiﬁed in Family 2 is c.5137-
10_2delAATTCCACA p.?. The consequence of this
change is not predictable but is likely to cause a skip of
exon 34, which would introduce a premature stop after the
inclusion of 20 aberrant amino acids.
Subject 6 was known to carry G to A substitution at
donor splice site of exon 21 (c.3695 + 1G4A p.?)
(Eunson et al., 2005). The consequence of this change
again is not predictable, but is likely to cause a skip of
exon 21, which would introduce a premature stop after
the inclusion of nine aberrant amino acids.
Subject 7 carries a mutation that introduces a premature
stop codon at the beginning of the C-terminus, c.5455C4T
p.Arg1819*, which was not identiﬁed in his parents. This
mutation has been previously reported in two unrelated
patients in association with EA2, absence seizures and cog-
nitive impairment (Jouvenceau et al., 2001; Strupp et al.,
2004) albeit as Arg1820* due to a different reference se-
quence being used. Subject 8 carries the previously reported
c.835C4T p.(Arg279Cys) mutation.
Nerve excitability studies
The mean data for subjects with EA2 and normal controls
are compared in Table 2. Prominent differences were found
in absolute electrical thresholds, threshold electrotonus and
the recovery cycle.
Stimulus–response and strength–duration
relationship
Subjects with EA2 exhibited an increased threshold. The
stimulus required to produce a CMAP 50% of the maximal
response was 85% greater in patients than controls [listed
in Table 2 as ‘Stimulus (mA) for 50% maximal CMAP’;
P = 0.009].
The strength–duration data are plotted in Fig. 2A as a
charge–duration plot (i.e. mA.ms versus ms). The strength–
duration time constant (sd) is given by the negative inter-
cept of the regression line on the x-axis, and the rheobase is
given by the slope of the regression line. The sd was not
signiﬁcantly different (Figs 2A and 3A), but mean rheobase
(i.e. threshold current for very long stimulus pulses) was
nearly twice as high in the affected individuals (Table 2),
and in four of eight cases was outside the 95% conﬁdence
limits for the normal controls (Fig. 3B). This is consistent
with the increased threshold for activation, noted in the
previous paragraph.
Threshold electrotonus
Averaged threshold electrotonus curves for the eight pa-
tients are compared to the mean for the 30 controls
(Fig. 2B). These graphs depict the change in threshold
during and after 100ms subthreshold conditioning currents
of  40% and 20% of the unconditioned threshold cur-
rent. There was a greater increase in excitability in response
to depolarizing currents in the patients and a greater de-
crease in excitability during hyperpolarization, producing a
‘fanning out’ appearance (Nodera and Kaji, 2006). These
differences are statistically signiﬁcant, especially for the
hyperpolarizing threshold electrotonus (Fig. 3B and D).
This is illustrated for TEd20(peak) (i.e. the greatest reduc-
tion in threshold during the 20% depolarizing current) in
Fig. 3C and for TEh40(90–100ms) (i.e. the increase in
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threshold at the end of the hyperpolarizing current, which
is 40% of threshold) in Fig. 3D.
Current–threshold relationship
The current–threshold relationship (Supplementary Fig. 1A)
measures the changes in threshold at the end of 200ms
currents, varied in strength from 50% of threshold
to100% of threshold. Because threshold is closely related
to membrane potential, this plot is a threshold analogue of
a current–voltage curve (Kiernan et al., 2000). Similarly,
the slope of this curve is a threshold analogue of input
conductance, designated ‘IV slope’ in Fig. 1B. There were
only modest differences between the subjects with EA2 and
controls (Table 2).
Recovery cycle
The excitability changes following supramaximal stimula-
tion are compared for the patients with EA2 and control
subjects in Fig. 2C. The patient recordings were character-
ized by a 13% shorter relative refractory period (white
arrow) and a 30% greater superexcitability (black arrow).
These differences are statistically signiﬁcant (Fig 3E, F and
Table 2), but there was no signiﬁcant difference in late
subexcitability.
Modelling
After optimizing its parameters (see ‘Materials and meth-
ods’ section), the model ﬁtted the control data with a re-
sidual discrepancy of 0.063. The discrepancy between this
control model and the mean EA2 axonal excitability data
was 1.15. To explore whether, for example, a change in
fast potassium channels could account for this discrepancy,
we determined the best reduction in discrepancy that could
be achieved by changing the fast potassium conductance at
nodes, internodes, or by making the same relative change in
both. The discrepancy reductions for these changes are
listed in Table 3 and were only 23.0, 22.3 and 23.9%,
respectively, so they could not provide a convincing explan-
ation for the altered excitability. Table 3 also lists the best
discrepancy reductions achieved by changing the 13 other
conductances, and also by changing the three capacitances
in the model, the resting membrane potential, and also the
half-activation voltage of the HCN channels. This mem-
brane property is sensitive to intracellular cyclic nucleotides
and other metabolic factors and most likely accounts for
much of the variability in nerve excitability properties be-
tween normal subjects, and the changes in inward rectiﬁca-
tion reported in some pathologies (Jankelowitz et al., 2007;
Lin et al., 2008; Howells et al., 2012). Interestingly, the
most appropriate changes in the model, resulting in a
73% reduction in discrepancy were made not by changes
in any ion channel, but by increasing the Barrett-Barrett
conductance (the conductance of the multiple pathways be-
tween the internodal axolemma and the exterior of the
nerve ﬁbre; see Barrett and Barrett, 1982). Figure 4 illus-
trates the excitability curves generated by the control model
and by the model for patient data. The control results are
in grey and the patient results in black, with the recorded
data shown in circles and the output of the model by con-
tinuous lines. For the patient data the modelled change was
a 13.7% increase in the Barrett-Barrett conductance. The
differences in excitability waveforms resemble those seen in
the recordings from controls and patients in Fig. 2. For
completeness, we also computed the best discrepancy re-
ductions achievable by altering the remaining 14 channel
gating parameters in the model (which are not listed in
Table 3, as there was no reason to suspect they might be
involved in EA2), but none of them reduced the discrep-
ancy by more than 31%.
Discussion
The present study has revealed disturbed excitability of
motor axons in eight subjects with genetically conﬁrmed
Table 1 Clinical and genetic features of patients with EA2
Family
(mutation)
Subject Age, sex Family
history
Clinical features
A
c.3992 + 1G4A
p.?
1 39; M Yes Onset age 6. Up to 4 episodes/week. Subtle interictal cerebellar findings.
2 39; F Yes Onset age 6. Up to 4 episodes a month. Normal interictal exam.
B
c.5137–10_–
2delAATTCCA
CA p.?
3 66; M Yes Onset age 7. Up to 4 episodes/week. Minor interictal cerebellar findings. Acetazolamide
ceased due to renal calculi.
4 40; M Yes Onset age 4. Up to 4 episodes/week. Normal exam.
5 34; F Yes Onset age 8. Up to 2 episodes/week. Normal exam. Acetazolamide ceased due to
thrombocytopaenia.
C
c.3695 + 1G4A
p.?
6 37; F Yes Onset age 6. Up to 4 episodes/month. Minor interictal cerebellar findings.
D
c.5455C4T
p.Arg1819*
7 21; M No Onset age 5 when started sports. Up to 2 episodes/week. Requires 4-AP in addition to
acetazolamide.
E
c.835C4T
p.(Arg279Cys)
8 48; F Yes Onset age 5. Normal interictal exam. Requires dichlorphenamide and topirimate in add-
ition to acetazolamide.
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EA2, with changes that can be modelled by an increase in
shunt conductance between the internodal axolemma and
exterior.
All subjects reported the onset of characteristic attacks
of cerebellar dysfunction lasting hours to days from
childhood. Two subjects from one kindred described
myasthenic-type weakness during attacks. All subjects
experienced a clinical response to acetazolamide though
this was incomplete in two. It could be anticipated
that acetazolamide would have affected measures of
axonal excitability, but this is unlikely to be signiﬁcant
at clinical dosages. It is therefore important that the
studies in the two patients not taking acetazolamide did
not differ signiﬁcantly from those taking the medication
at the time of the study. Three of eight subjects had subtle
ﬁxed cerebellar signs between attacks. Cerebellar ataxia
is consistent with dysfunction of central synapses;
however, Cav2.1 is also expressed in peripheral motor
Figure 1 Single-fibre EMG studies in EA2. (A–C) Increased jitter with blocking in Subject 5 (Family 2). (A) Superimposed traces of single fibre
EMG during recordings during voluntary contraction demonstrating increased jitter, reflecting instability of the neuromuscular junction. (B and C)
Same recording displayed in raster mode showing increased jitter and blocking. (D) Stimulation single-fibre EMG in EA2. Stimulation rates are 1, 2, 5,
10, 15 and 20 Hz. Maximal jitter is seen at 2–5Hz stimulation, decreasing at higher rates, similar to the findings in Lambert-Eaton syndrome.
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axons, albeit conﬁned to the neuromuscular junction
(Vogel and Schwarz, 1995). Nevertheless, the
measurements of axonal excitability at the wrist
detected signiﬁcant differences between the EA2 cohort
and normal control subjects. The possible reasons
for these altered excitability properties are discussed
below.
Abnormal neuromuscular transmis-
sion in episodic ataxia type 2
Cav2.1 is highly expressed at the neuromuscular junction
where it is closely associated with neurotransmitter exo-
cytic machinery (Protti et al., 1996; Plant et al., 1998).
As a result of an action potential, Cav2.1 activation
Table 2 Comparison between nerve excitability measurements in EA2 and in normal controls
Control EA2 t(df)a Pb
(n = 30) (n = 8)
Stimulus-response and strength-duration properties
Stimulus (mA) for 50% maximal CMAPc 4.29  /U 1.04 7.95  /U 1.19 3.49(7.59) 0.0090**
Peak CMAP (mV)c 8.66  /U 1.04 8.57  /U 1.05 0.14(22.8) 0.86
Strength-duration time constant (ms) 0.48  0.018 0.45  0.031 0.98(12.3) 0.35
Rheobase (mA)c 2.80  /U 1.04 5.33  /U 1.19 3.64(7.7) 0.0070**
Threshold electrotonus
TEd40(peak) (%) 68.17  0.70 72.28  0.90 3.61(16.38) 0.0023**
TEd40(90 100 ms) (%) 43.96  0.66 47.15  1.16 2.39(12.01) 0.033*
TEd20(peak) (%) 38.19  0.52 42.28  0.82 4.21(13.41) 0.0010**
TEh20(90100 ms) (%) 47.1  1.0 56.7  2.7 3.36(7.8) 0.010*
TEh40(2040 ms) (%) 91.11  1.25 100.2  1.67 4.38(15.82) 0.00053***
TEh40(90100 ms) (%) 116.7  2.77 138.6  3.19 5.18(18.99) 0.000068****
Current-threshold properties
Resting I/V slope 0.607  0.014 0.54  0.031 1.96(10.18) 0.075
Minimum I/V slope 0.246  0.008 0.224  0.011 1.6(15.21) 0.13
Hyperpolarizing I/V slope 0.341  0.010 0.377  0.024 1.35(9.77) 0.21
Recovery cycle
RRP (ms)c 2.95  /U 1.02 2.58  /U 1.02 4.64(20.79) 0.00017***
Superexcitability (%) 23.05  0.93 30.39  1.91 3.45(10.52) 0.0057**
Subexcitability (%) 14.4  0.65 15.07  0.76 0.66(18.76) 0.52
Subjects/recording
Age (years) 39.1  2.4 (30) 40.6  4.5 (8) 0.30 (11.23) 0.76
Sex (male = 1, female = 2) 1.47  0.09 (30) 1.5  0.19 (8) 0.16(10.62) 0.85
Temperature 33.25  0.17 (30) 33.86  0.26 (8) 1.95(13.41) 0.070
For definition of excitability measurements see Glossary.
Values are mean  SEM, except for four measurementsc.
at and degrees of freedom for Welch’s unequal variance t-test.
bP indicates probability for two-tailed test *P5 0.05, **P5 0.01, ***P5 0.001, ****P5 0.0001.
cValues were normalized by log conversion and given as geometric mean  /U standard error expressed as a factor.
Figure 2 Axonal excitability measurements in Subjects with EA2 compared to controls. (A) Strength–duration time constant is
given by the negative intercept of the regression line on the x-axis (open arrow). Rheobase is given by the slope of the regression line (filled
arrow). (B) Threshold electrotonus in patients with EA2 and control subjects. Each point is mean  SEM. Filled circles = EA2 (n = 8). Open arrow
indicates increase in TEd in patients with EA2. Black arrow indicates increase in TEh in patients with EA2. (C) The recovery cycle in EA2. The
patients’ recordings are characterized by a 12% shorter relative refractory period (open arrow) and a 24% increase in superexcitability (closed
arrow).
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facilitates calcium-dependant acetylcholine release. In the
autoimmune disease Lambert-Eaton myasthenic syn-
drome (LEMS), antibodies directed against Cav2.1
impair presynaptic acetylcholine release producing
muscle weakness. In these patients, the jitter and block-
ing is maximal at stimulation rates of5Hz and reduces
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Figure 3 Dot plots illustrating individual data points in EA2 subjects compared to controls. (A) Strength duration time constant.
(B) Rheobase. (C) Peak threshold decrease with 20% depolarizing current. (D) Threshold electrotonus with 40% hyperpolarizing current. (E)
Relative refractory period (RRP). (F) Peak superexcitability in recovery cycle. NC = normal controls; NS = not significant. Asterisks indicate level
of significance by Welch unequal variance t-test, as in Table 2. Note logarithmic axes in B and E to help normalize distributions. Horizontal lines
indicate means (solid) and means  standard error (dotted).
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at higher rates (Trontelj and Sta˚lberg, 1991; Mills,
2005). The stimulated single ﬁbre EMG ﬁndings in
Subject 5 (in Family 2) closely parallel the ﬁndings in
LEMS and is consistent with impaired Cav2.1 function.
Repetitive activation at high frequency (e.g. 20–50Hz)
restores neurotransmission (Mills, 2005). It is not sur-
prising therefore that similar clinical and neurophysio-
logical ﬁndings have been reported in patients with
EA2. In the recovery cycle, it is conceivable that the con-
ditioning discharge would affect transmission at the
neuromuscular junction. In patients with LEMS, this
could change the test CMAP at the intervals used in
the recovery cycle (45Hz), producing equivalent
changes in threshold. However, the two patients who
had abnormal stimulated single ﬁbre EMG had no
abnormalities on repetitive stimulation and their recov-
ery cycle data were not signiﬁcantly different from those
of the other six patients.
Axonal excitability in episodic ataxia type 2
This paper reports alterations in the excitability properties
of motor axons in the nerve trunk in patients with EA2.
Acetazolamide was not discontinued prior to the study, but
as noted above, the same excitability changes were seen in
the two patients in whom the medication had been discon-
tinued for medical reasons. The features seen in patients
with EA2 include an increase in threshold, a shortened
relative refractory period and greater threshold changes to
the changes in membrane potential seen in threshold elec-
trotonus. These abnormalities are qualitatively similar to
those in EA1 (Tomlinson et al., 2010). However,
some measures behaved differently, and this was not just
qualitative. For example, late subexcitability was normal in
EA2 (Table 2) whereas it was increased in the 20 patients
with EA1, so that the difference between the two types of
episodic ataxia was highly signiﬁcant (EA2: 14.4  0.65%;
EA1: 24.1  1.7%; mean  SE, P5 0.0001, Welch test).
There was greater accommodation to 40% depolarizing
currents in EA1 (EA2: 15.07  0.7%; EA1:
23.41  1.59% P5 0.00001). Also, although superexcit-
ability was increased in both groups, it was increased
much more in EA1 (EA2:30.39  1.9%;
EA1:44.3  1.8%, P5 0.0001). Low serum potassium
can produce some of the features seen in EA2 (Boe¨rio
et al., 2014). These include increased threshold change to
hyperpolarization in threshold electrotonus and increased
superexcitability. However, low serum potassium would
have also increased the threshold change to depolarization
and increased late subexcitability. These changes were not
seen in the EA2 cohort.
Underlying mechanisms
Whereas the nerve excitability changes in the EA1 subjects
can be attributed directly to the loss of Kv1.1 fast potas-
sium channels (Tomlinson et al., 2010), the same mechan-
ism cannot be responsible for the superﬁcially similar but
less severe changes in EA2. A quantitative model of motor
nerve excitability, previously used to account for the excit-
ability changes induced by puffer ﬁsh poisoning (Kiernan
et al., 2005a), showed that the single parameter change that
best explained the differences between patients and controls
was a 14% increase in the conductance path across and
around the myelin sheath, also known as the Barrett-
Barrett conductance (Barrett and Barrett, 1982) (Table 3
Table 3 Modelling possible explanations of altered nerve excitability properties in EA2.
Model parameter Control value Best fit value Units Discrepancy Discrepancy reduction
(%)
Barrett-Barrett conductance 36.5 41.5 nS 0.311 73.0
Resting potential (altered by applied current) 82.3 83.4 mV 0.483 58.1
Internodal leak conductance 3.6 1.83 nS 0.503 56.3
Nodal and internodal leak conductances (rel) 1.0 0.61 - 0.504 56.3
Nodal leak conductance 1.08 0.17 nS 0.674 41.5
HCN channel half-activation voltage 103.1 109.9 mV 0.799 30.2
Slow potassium conductances (rel) 1.0 0.835 - 0.832 27.9
Nodal slow potassium conductance 50.8 42.3 nS 0.834 27.7
Fast potassium conductances (rel) 1.0 0.83 - 0.878 23.9
Nodal fast potassium conductance 19.9 15.7 nS 0.887 23.0
Internodal fast potassium conductance 100 62 nS 0.895 22.3
Persistent sodium permeability (% transient) 1.02 1.12 % 0.956 17.0
HCN channel conductance 5.15 3.5 nS 0.960 16.8
Transient sodium permeability 3.75 4.0 cm3s1.109 0.998 13.4
Internodal slow potassium conductance 0.33 0.40 nS 1.12 2.2
Capacitance internodal axon 0.273 0.257 nF 1.13 1.6
Capacitance node 0.50 0.53 pF 1.15 0.6
Capacitance myelin 1.55 1.55 pF 1.15 0.0
List of best fits to the EA2 patient nerve excitability data made by changing a single parameter in the model first fitted to the normal control data. For example, increasing the Barrett-
Barrett conductance from 36.5 to 41.5 nS reduces the discrepancy between the model and the EA2 data from 1.15 to 0.311, a reduction of 73%. The parameters designated ‘(rel)’ are
factors applied to both nodal and internodal conductances of the same type.
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and Fig. 4). The modelling suggests that the altered axonal
excitability arises from quite different mechanisms in EA1
and EA2, and in EA2 is more likely due to changes in
Schwann cell ensheathment than in axonal ion channels.
According to this interpretation, the superﬁcial similarity
in excitability changes in threshold electrotonus and in
the recovery cycle arises because in each case, both applied
currents and the current generated during the nerve impulse
cause a greater change in the membrane potential of the
internodal axon: in EA1 this is because the internodal axo-
lemma has fewer Kv1.1 channels to resist potential change,
whereas in EA2 the access resistance restricting current
ﬂow to the internodes is lower. Comparison between
Fig. 4 and Fig. 2 show that there is a good correspondence
between the other excitability abnormalities recorded in
EA2 and the predicted effects of increasing the Barrett-
Barrett conductance, supporting the high discrepancy re-
duction for this parameter [which at 73% was almost as
great as the 75% discrepancy reduction reported by
Kiernan et al. (2005a) when recordings from patients
with puffer ﬁsh poisoning were modelled by a reduction
in sodium channel permeability]. While this level of ‘good-
ness of ﬁt’ obtained by changing the Barrett-Barrett con-
ductance provides a strong pointer to the nature of the
abnormality, it cannot prove that this pathway is involved,
and to ﬁnd a plausible mechanism relating this interpret-
ation to the calcium channel defect we must look else-
where. Such a mechanism is suggested by the report of
Figure 4 Difference between control and EA2 nerve excitability modelled as an increase in Barrett-Barrett conductance. The
control results are in grey and the patient results in black, with the recorded data shown in circles and the output of the model by continuous
lines. For the patient data the modelled change was a 13.7% increase in the Barrett-Barrett conductance. (A) Threshold electrotonus.
(B) Recovery cycle. (C) Current/threshold reduction curve. (D) I/V slope.
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Alix et al. (2008), who observed transient expression of
1A subunit of P/Q calcium channels along the axolemma
of optic nerve axons during early neonatal development in
mice. Mutation in the CACNA1A gene caused malforma-
tion of the nodes of Ranvier, with disordered localization
of nodal proteins including voltage-gated sodium channels,
b IV spectrin and contactin-associated protein-1 (CASPR1,
encoded by CNTNAP1). If the P/Q calcium channels pre-
sent in peripheral nerve axons during development have a
similar role, it is likely that the changes in excitability in
peripheral nerve axons described here reﬂect the sustained
impact of nodal malformation in the early neonatal period.
The mathematical modelling is consistent with this hypoth-
esis. Interestingly, studies from infancy to adulthood by
Farrar et al. (2013) have demonstrated changes in excitabil-
ity that are generally consistent with those described in
EA2, and were attributed to maturational changes at the
axo–glial junction.
In conclusion, the excitability properties of peripheral
motor axons in EA2 differ signiﬁcantly from those in
normal controls, and also from those in EA1. The pat-
tern of excitability changes in EA2 may result from nodal
malformation in the neonatal period. As was the case
with our previous study of patients recovered from
benign familial neonatal epilepsy (Tomlinson et al.,
2012), this study demonstrates the power of excitability
studies to detect membrane abnormalities that are too
subtle to produce symptoms or to be detected by routine
neurophysiological studies. In addition, this study raises
a further mechanism through which peripheral nerve
axons can be altered in disorders that are primarily cen-
tral (Kiernan et al., 2005b; Jankelowitz et al., 2007; Ng
et al., 2008; Boland et al., 2009; Tomlinson et al., 2010,
2012) even when the relevant channel is not normally
expressed at the site of stimulation. Indirect conse-
quences of inherited channelopathies should be taken
into account when considering the circuit consequences
of the ion channel defect. However, in their recent study,
Zhang and David (2016) used Ca2+ imaging to provide
evidence for T-type (Cav3.x) Ca2+ channels at the node
of Ranvier and L-type (Cav1.x) channels on the parano-
dal or juxtaparanodal membrane of myelinated motor
axons of the mouse. When axons were stimulated at
50Hz for 10 s, there was a small increase in axoplasmic
[Ca2+ ] at the node, and this was greater when there was
paranodal demyelination. They found no evidence for the
involvement of Cav2.1 channels, so our conclusions are
not directly affected, but it can no longer be maintained
with conﬁdence that Ca2+ channels are not present at the
node of Ranvier of human motor axons.
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